Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20662 | 0.91 | — | — | |
| SCHEMBL27423032 | 0.89 | ABCG2 (0.46) | ABCG2CYP3A4ALDH1A1HSD17B10TDP1 | |
| SCHEMBL27765909 | 0.88 | ITGB2 (0.41) | — | |
| SCHEMBL20741878 | 0.78 | ABCG2 (0.33) | ABCG2 | |
| SCHEMBL20030 | 0.78 | ITGB2 (0.48) | ABCG2ALDH1A1 | |
| SCHEMBL27343450 | 0.76 | ITGB2 (0.46) | — | |
| SCHEMBL4986425 | 0.74 | — | — | |
| SCHEMBL106413 | 0.74 | ITGB2 (0.39) | ALDH1A1 | |
| SCHEMBL20741840 | 0.73 | ITGB2 (0.34) | ABCG2 | |
| SCHEMBL11748070 | 0.72 | LMNA (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774108-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20170342102-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774108-B2 | Compositions and methods for treating CNS disorders | GRIN2B, ADRA2B, ADRA1B | ABCG2 1787/4885CYP3A4 370/4885ALDH1A1 578/4885 |
| US-20170342102-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | ABCG2 1787/4885CYP3A4 370/4885ALDH1A1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.